Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in healthy volunteers

被引:36
作者
Calabresi, L
Pazzucconi, F
Ferrara, S
di Paolo, A
Del Tacca, M
Sirtori, C
机构
[1] Univ Milan, Dept Pharmacol Sci, Ctr E Grossi Paoletti, I-20133 Milan, Italy
[2] Univ Pisa, Dipartiment Oncol, I-56100 Pisa, Italy
关键词
clarithromycin; omeprazole; pantoprazole; proton pump inhibitors; drug interactions;
D O I
10.1016/j.phrs.2003.10.010
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The association omeprazole/clarithromycin is of current wide use in the treatment of Helicobacter pylori associated gastroduodenal ulcer. This combination may result in increased levels of omeprazole with potential interactions with commonly associated drugs. Kinetic/metabolic changes occurring after orneprazole/clarithromycin were compared to those occurring after pantoprazole/clarithromycin in healthy volunteers. Eight healthy volunteers, all males, age 25-34 years, all EM for CYP2C19, participated in a randomized, double blind crossover study in two periods of 7 days, separated by a 14-day washout. In each treatment period, subjects took either omeprazole 20 mg b.i.d. together with clarithromycin 500 mg b.i.d., or pantoprazole 40 mg b.i.d. with the same dose of the antibiotic. The pharmacokinetic parameters of omeprazole and pantoprazole were compared to those after intake of both agents alone. Kinetics of unchanged clarithromycin was evaluated at the end of the two periods. The mean value of the area under the plasma concentration versus time curve (AUC) of unchanged omeprazole increased almost two-fold after concomitant administration of clarithromycin; the average 5-OH-omeprazole AUC was instead significantly reduced by 42%. Omeprazole clearance and volume of distribution were reduced significantly by 75 and 56%, respectively, after administration of the drug with clarithromicyn. No significant changes of the kinetic of pantoprazole and metabolites were observed. Kinetics of clarithromycin did not differ after the two associated treatments. The administration of clarithromycin with two different proton pump inhibitors indicates that the antibiotic can markedly increase omeprazole, not pantoprazole, levels. This observation may result in a better therapeutic response to omeprazole, but it may also potentially affect either the metabolism of CYP3A4 substrates or interfere with the absorption of drugs requiring an intact gastric digestion system. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:493 / 499
页数:7
相关论文
共 37 条
[1]   IDENTIFICATION OF HUMAN LIVER CYTOCHROME-P450 ISOFORMS MEDIATING SECONDARY OMEPRAZOLE METABOLISM [J].
ANDERSSON, T ;
MINERS, JO ;
VERONESE, ME ;
BIRKETT, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (06) :597-604
[2]   Grapefruit juice-drug interactions [J].
Bailey, DG ;
Malcolm, J ;
Arnold, O ;
Spence, JD .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 (02) :101-110
[3]  
Bliesath H, 1996, INT J CLIN PHARM TH, V34, P51
[4]   Effect of acid secretion blockade by omeprazole on the relative bioavailability of orally administered furazolidone in healthy volunteers [J].
Calafatti, SA ;
Ortiz, RAM ;
Deguer, M ;
Martinez, M ;
Pedrazzoli, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (02) :205-209
[5]   New insights into the pharmacodynamic and pharmacokinetic properties of statins [J].
Corsini, A ;
Bellosta, S ;
Baetta, R ;
Fumagalli, R ;
Paoletti, R ;
Bernini, F .
PHARMACOLOGY & THERAPEUTICS, 1999, 84 (03) :413-428
[6]   Does differing metabolism by cytochrome p450 have clinical importance? [J].
Davidson M.H. .
Current Atherosclerosis Reports, 2000, 2 (1) :14-19
[7]  
DEMORAIS SMF, 1994, MOL PHARMACOL, V46, P594
[8]   Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition [J].
Dresser, GK ;
Spence, JD ;
Bailey, DG .
CLINICAL PHARMACOKINETICS, 2000, 38 (01) :41-57
[9]   Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans [J].
Furuta, T ;
Ohashi, K ;
Kobayashi, K ;
Iida, I ;
Yoshida, H ;
Shirai, N ;
Takashima, M ;
Kosuge, K ;
Hanai, H ;
Chiba, K ;
Ishizaki, T ;
Kaneko, E .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (03) :265-274
[10]   CΥP2C19 genotype status and effect of omeprazole on intragastric pH in humans [J].
Furuta, T ;
Ohashi, K ;
Kosuge, K ;
Zhao, XJ ;
Takashima, M ;
Kimura, M ;
Nishimoto, M ;
Hanai, H ;
Kaneko, E ;
Ishizaki, T .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (05) :552-561